Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
Provention Bio has dosed the first lupus patient enrolled in the Phase 1b/2 trial testing the safety and pharmaceutical properties of its experimental B-cell-targeted therapy PRV-3279. Results from the ... Read more
Changes in gut bacteria, or microbiota, during pregnancy and lactation can shift the immune response towards a more pro-inflammatory state that can bolster autoimmune responses and worsen lupus, a ... Read more
In studying how mycophenolate mofetil treatment affects immune cells and blood markers in people with systemic lupus erythematosus (SLE), researchers uncovered an immune pathway that may explain why is lupus suppressed ... Read more
Tofacitinib tablets, a medicine approved to treat rheumatoid and psoriatic arthritis, may work for lessening signs and symptoms of arthritis and skin rash in people with systemic lupus erythematosus ... Read more
GlaxoSmithKline (GSK) is recruiting participants for a Phase 3 clinical trial to evaluate the effectiveness and safety of Benlysta (belimumab) in combination with rituximab for treating patients with active systemic lupus erythematosus (SLE). The study ... Read more
Rituxan (rituximab) is not effective at treating moderate to severe systemic lupus erythematosus (SLE) patients without kidney involvement, a new analysis of the Phase 2/3 trial EXPLORER concluded. The results ... Read more